Cancer
01 Jan 2013
Study of SU011248 in Patients with Neuroendocrine Tumors
The primary objective of the study is to determine the efficacy and safety of SU011248 as a treatment for patients with advanced unresectable neuroendocrine tumor; however, CURRENTLY ONLY RECRUITING FOR PATIENTS SPECIFICALLY WITH PANCREATIC ISLET CELL TUMORS. Official Title Phase II Study of SU011248 in Patients with Neuroendocrine Tumors; however,…
Cancer
01 Jan 2013
Study of SU011248 in Patients with Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel. Official Title A Phase 2 Efficacy and Safety Study of SU011248 in Patients with Metastatic Non-Small Cell Lung…
Cancer
01 Jan 2013
FOLFOX4 in Patients with Normal and Abnormal Renal Function
This trial is a phase II study of patients with advanced gastrointestinal (GI) malignancies who will be assigned to one of 4 cohorts (normal, mild dysfunction, moderate dysfunction and severe renal dysfunction) based on their baseline measured creatinine clearance then treated with FOLFOX4. Standard bone marrow and liver function…
Cancer
01 Jan 2013
Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
In this Phase IIIb, randomized, double-blind, maintenance study, 300 subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) (Stage IIIB {T4-pleural effusion} and IV) who have SD or objective tumor response immediately following the completion of 4-6 cycles of front line, platinum-based, doublet chemotherapy will be randomized in a…
Cancer
01 Jan 2013
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC). Official Title A Phase…
Cancer
01 Jan 2013
FASLODEX and AROMASIN in Hormone Receptor Positive Postmenopausal Women with Advanced Breast Cancer
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient,…
Cancer
01 Jan 2013
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than…
Cancer
01 Jan 2013
Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer
RATIONALE: An outpatient educational and behavioral skills training program may help patients with metastatic breast or prostate cancer live longer and more comfortably. PURPOSE: Randomizedpilot study to evaluate whether an outpatient educational and behavioral skills training program will improve pain control in patients who have metastatic or recurrent breast…
Cancer
01 Jan 2013
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin’s Lymphoma
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether chemotherapy is…
